Caris Life Sciences Q2 FY26 net loss narrows to USD 0.6 million; revenue rises 45% to USD 263.7 million
PUBT · 3d ago
Share
Listen to the news
- Caris Life Sciences posts Q2 2026 revenue of USD 263.7 million, up 45% year over year.
- Net loss narrows to USD 0.6 million; gross margin rises 5 percentage points to 68%.
- Adjusted EBITDA (non-GAAP) climbs to USD 55.7 million; operating cash flow increases to USD 28.5 million.
- Clinical cases rise 18% to 59,200; the company launched Caris Detect multi-cancer early detection test.
- Raises 2026 revenue guidance to USD 1.03 billion-USD 1.04 billion; CEO David Dean Halbert calls it a record quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608051605PR_NEWS_USPR_____DA19379) on August 05, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending